You are here
Different EGFR/KRAS mutation spectrums in lung cancer between never smokers and heavy smokers.
J Clin Oncol 30, 2012 (suppl; abstr 10548)
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).
Background: EGFR mutations are more commonly found in lung adenocarcinomas in never smokers, while KRAS mutations are more frequently present in those in heavy smokers. Although the incidence is low, EGFR mutations are also found in tumors in heavy smokers and KRAS mutations also occur in tumors in never smokers. Therefore, there may be different biological characteristics in EGFR/ KRAS mutated lung cancers according to the smoking status. Methods: This was a retrospective review of 382 patients with surgically resected lung cancers between February 2009 and March 2011. The clinicopathological factors (age, gender, histology, serum CEA level, pathological nodal status, lymphatic permeation, and blood vessel invasion) and EGFR/KRAS mutation spectrums were compared between never smokers (pack-year = 0, n = 161) and heavy smokers (pack-year > 20, n = 167). Results: EGFR mutations were detected in 88 (55%) never smokers and in 33 (20%) heavy smokers. In contrast, K-ras mutations were detected in 7 (4%) never smokers and in 31 (19%) heavy smokers. Both EGFR and KRAS mutations were more frequently observed in female never smokers and in male heavy smokers. The spectrum of both EGFR and KRAS mutation differed according to the smoking status. Minor EGFR mutations other than exon 21 L858R and exon 19 deletions that are activating mutations indicating the efficacy of EGFR tyrosine kinase inhibitors (TKIs) were more frequently found in heavy smokers than in never smokers. G→A transitions were more common KRAS mutations in never smokers and G→T transversions that are thought to be related to exposure to the polycyclic aromatic hydrocarbons found in cigarette smoke were more common KRAS mutations in heavy smokers. Conclusions: The EGFR/KRAS mutation spectrums in lung cancer were quite different in never smokers and heavy smokers. Further study is needed to evaluate the relationship between the efficacy of such molecular targeting agents as EGFR TKIs and the EGFR/KRAS mutation spectrums.
Abstracts by Kazuya Takamochi:
Are the criteria indicating patients to be “medically inoperable” that are used in clinical trials on stereotactic body radiotherapy appropriate for patients with early-stage non-small cell lung cancer?
Detection of circulating tumor cells with epithelial-mesenchymal transition phenotype as critical surrogate biomarkers in patients with non-small cell lung cancer.Category: Tumor Biology - Circulating Tumor Cells
- Meeting: 2014 ASCO Annual Meeting | Abstract No: e18513
Presentations by Kazuya Takamochi:
Combined mutation pattern analyses of EGFR and K-ras for the differential diagnosis of primary versus metastatic lung adenocarcinomas.Session: General Poster Session B (General Poster Session)
Are the criteria indicating patients to be ?medically inoperable? that are used in clinical trials on stereotactic body radiotherapy appropriate for patients with early-stage non-small cell lung cancer?Session: Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers (General Poster Session)